Are Older People Aware of Potential Risks Related to Benzodiazepines They are Taking and Has Anything Changed in Risk Awareness Over Ten Years?

References

• Roehrs T, Roth T. Insomnia pharmacotherapy. Neurotherapeutics. 2012;9(4):728–738. doi:10.1007/s13311-012-0148-3
   PubMed Web of Science ®Google Scholar
• Starcevic V. Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks. Adv Psychiatr Treat. 2012;18(4):250–258. doi:10.1192/apt.bp.110.008631
   Google Scholar
• Insomnia. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Sleep Research Society. Helsinki: The Finnish Medical Society Duodecim 2015. Finnish. Available from: www.kaypahoito.fi/web/kh/suositukset/suositus?id=hoi50067. Accessed November 29, 2020.
   Google Scholar
• By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694. doi:10.1111/jgs.15767
   PubMed Web of Science ®Google Scholar
• Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295–301. doi:10.1111/j.1365-2125.2012.04418.x
   PubMed Web of Science ®Google Scholar
• Crowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901–911. doi:10.1093/arclin/acx120
   PubMed Web of Science ®Google Scholar
• Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol a Biol Sci Med Sci. 2007;62(10):1172–1181. doi:10.1093/gerona/62.10.1172
   PubMed Web of Science ®Google Scholar
• Nurminen J, Puustinen J, Piirtola M, Vahlberg T, Kivelä SL. Psychotropic drugs and the risk of fractures in old age: a prospective population-based study. BMC Public Health. 2010;10(1):396. doi:10.1186/1471-2458-10-396
   Web of Science ®Google Scholar
• Smink B, Egberts A, Lusthof K, Uges D, de Gier J. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs. 2010;24(8):639–653. doi:10.2165/11533170-000000000-00000
   PubMed Web of Science ®Google Scholar
• Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136–142. doi:10.1001/jamapsychiatry.2014.1763
   PubMed Web of Science ®Google Scholar
• Huerta C, Abbing‐Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):56–65. doi:10.1002/pds.3825
   PubMed Web of Science ®Google Scholar
• Kurko T, Saastamoinen LK, Tuulio-Henriksson A, et al. Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014. Pharmacoepidemiol Drug Saf. 2018;27(6):674–682. doi:10.1002/pds.4551
   PubMed Web of Science ®Google Scholar
• Mah L, Upshur R. Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. BMC Fam Pract. 2002;3(1):9. doi:10.1186/1471-2296-3-9
   Google Scholar
• Iliffe S, Curran H, Collins R, Yuen Kee S, Fletcher S, Woods B. Attitudes to long-term use of benzodiazepine hypnotics by older people in general practice: findings from interviews with service users and providers. Aging Ment Health. 2004;8(3):242–248. doi:10.1080/13607860410001669778
   PubMed Web of Science ®Google Scholar
• Parr JM, Kavanagh DJ, Young RM, McCafferty K. Views of general practitioners and benzodiazepine users on benzodiazepines: a qualitative analysis. Soc Sci Med. 2006;62(5):1237–1249. doi:10.1016/j.socscimed.2005.07.016
   PubMed Web of Science ®Google Scholar
• Anthierens S, Habraken H, Petrovic M, Deveugele M, De Maeseneer J, Christiaens T. First benzodiazepine prescriptions: qualitative study of patients’ perspectives. Can Fam Physician. 2007;53(7):1200–1201.
   PubMedGoogle Scholar
• Cook JM, Biyanova T, Masci C, Coyne JC. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med. 2007;22(8):1094–1100. doi:10.1007/s11606-007-0205-5
   PubMed Web of Science ®Google Scholar
• Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. Magic bullets for insomnia? Patients’ use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br J Gen Pract. 2008;58(551):417–422. doi:10.3399/bjgp08X299290
   PubMed Web of Science ®Google Scholar
• Sake F, Wong K, Bartlett D, Saini B. Benzodiazepine use risk: understanding patient specific risk perceptions and medication beliefs. Res Social Adm Pharm. 2019;15(11):1317–1325. doi:10.1016/j.sapharm.2018.12.007
   PubMed Web of Science ®Google Scholar
• Webster RK, Weinman J, Rubin GJ. People’s understanding of verbal risk descriptors in patient information leaflets: a cross-sectional national survey of 18- to 65-year-olds in England. Drug Saf. 2017;40(8):743–754. doi:10.1007/s40264-017-0542-1
   Web of Science ®Google Scholar
• Aronson JK. Risk perception in drug therapy. Br J Clin Pharmacol. 2006;62(2):135–137. doi:10.1111/j.1365-2125.2006.02739_1.x
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi:10.1016/0022-3956(75)90026-6
   PubMed Web of Science ®Google Scholar
• European Commission. A guideline on summary of product characteristics; 2009. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Accessed November 29, 2020..
   Google Scholar
• Finnish Advisory Board on Research Integrity. Responsible conduct in research and procedures for handling allegations of misconduct in Finland. Available from: https://www.tenk.fi/en/tenk-guidelines. Accessed November 29, 2020.
   Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• Leikola S, Dimitrow M, Lyles A, Pitkälä K, Airaksinen M. Potentially inappropriate medication use among Finnish non-institutionalized people aged ≥65 years: a register-based, cross-sectional, national study. Drugs Aging. 2011;28(3):227–236. doi:10.2165/11586890-000000000-00000
   PubMed Web of Science ®Google Scholar
• Salonoja M, Salminen M, Aarnio P, Vahlberg T, Kivelä SL. One-time counselling decreases the use of benzodiazepines and related drugs among community-dwelling older persons. Age Ageing. 2010;39(3):313–319. doi:10.1093/ageing/afp255
   Web of Science ®Google Scholar
• Salonoja M, Salminen M, Vahlberg T, Aarnio P, Kivelä SL. Withdrawal of psychotropic drugs decreases the risk of falls requiring treatment. Arch Gerontol Geriatr. 2012;54(1):160–167. doi:10.1016/j.archger.2011.02.015
   Web of Science ®Google Scholar
• Lahteenmaki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975–985. doi:10.1111/bcp.12294
   Web of Science ®Google Scholar
• Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients’ experiences and perceptions of seeking and using benzodiazepines and Z-drugs: towards safer prescribing. Patient. 2017;10(1):1–15. doi:10.1007/s40271-016-0182-z
   Google Scholar
• Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized Trial. JAMA Intern Med. 2014;174(6):890–898. doi:10.1001/jamainternmed.2014.949
   PubMed Web of Science ®Google Scholar
• The Finnish Medicines Agency: Meds75+. Available from: http://www.fimea.fi/web/en/databases_and_registeries/medicines_information/database_of_medication_for_the_elderly. Accessed November 29, 2020.
   Google Scholar
• Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69(4):1–10. doi:10.1007/s00228-012-1424-1
   PubMed Web of Science ®Google Scholar
• Wade A, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597–2605. doi:10.1185/030079907X233098
   PubMed Web of Science ®Google Scholar
• Wade A, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BioMed Central Med. 2010:8. doi:10.1186/1741-7015-8-51.
   Google Scholar